Axonics gets regulatory nod for fourth-generation rechargeable SNM system in Australia
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 26 2024
0mins
Should l Buy ?
Source: SeekingAlpha
Regulatory Approval: Axonics has received approval from the Therapeutic Goods Administration in Australia to market its R20 rechargeable sacral neuromodulation system for treating overactive bladder and fecal incontinence in adults.
Product Features: The R20 neurostimulator is designed specifically for these conditions, enhancing treatment options for patients suffering from these issues.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
